CoChat

Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial

Open access

The DOI matches its Crossref record; 28 of the 28 references it cites were found in a registry or an index.

Abstract

Background Abrocitinib, an oral selective Janus kinase 1 inhibitor, was effective and well tolerated in adults with moderate-to-severe atopic dermatitis in a phase 2b trial. We aimed to assess the efficacy and safety of abrocitinib monotherapy in adolescents and adults with moderate-to-severe atopic dermatitis.Methods In this multicentre, double-blind, randomised phase 3 trial (JADE MONO-1), patients (aged ≥12 years) with moderate-to-severe atopic dermatitis (Investigator Global Assessment score ≥3, Eczema Area and Severity Index [EASI] score ≥16, percentage of body surface area affected ≥10%, and Peak Pruritus Numerical Rating Scale score ≥4) with a bodyweight of 40 kg or more, were enrolled at 69 sites in Australia, Canada, Europe, and the USA. Patients were randomly assigned (2:2:1) to oral abrocitinib 100 mg, abrocitinib 200 mg, or placebo once daily for 12 weeks. Randomisation was done using an interactive response technology system, stratified by baseline disease severity and age. Patients, investigators, and the funder of the study were masked to study treatment. The coprimary endpoints were the proportion of patients who had achieved an Investigator Global Assessment response (score of 0 [clear] or 1 [almost clear] with a ≥2-grade improvement from baseline), and the proportion of patients who achieved at least a 75% improvement in EASI score from baseline (EASI-75) score, both assessed at week 12. Efficacy was assessed in the full analysis set, which included all randomised patients who received at least one dose of study medication. Safety was assessed in all randomised patients. This study is registered with ClinicalTrials.gov, NCT03349060.Findings Between Dec 7, 2017, and March 26, 2019, 387 patients were enrolled: 156 were assigned to abrocitinib 100 mg, 154 to abrocitinib 200 mg, and 77 to placebo. All enrolled patients received at least one dose of study treatment and thus were evaluable for 12-week efficacy. Of the patients with available data for the coprimary endpoints at week 12, the proportion of patients who had achieved an Investigator Global Assessment response was significantly higher in the abrocitinib 100 mg group than in the placebo group (37 [24%] of 156 patients vs six [8%] of 76 patients; p=0·0037) and in the abrocitinib 200 mg group compared with the placebo group (67 [44%] of 153 patients vs six [8%] of 76 patients; p<0·0001). Of the patients with available data for the coprimary endpoints at week 12, compared with the placebo group, the proportion of patients who had achieved an EASI-75 response was significantly higher in the abrocitinib 100 mg group (62 [40%] of 156 patients vs nine [12%] of 76 patients; p<0·0001) and abrocitinib 200 mg group (96 [63%] of 153 patients vs nine [12%] of 76 patients; p<0·0001). Adverse events were reported in 108 (69%) of 156 patients in the abrocitinib 100 mg group, 120 (78%) of 154 patients in the abrocitinib 200 mg group, and 44 (57%) of 77 patients in the placebo group. Serious adverse events were reported in five (3%) of 156 patients in the abrocitinib 100 mg group, five (3%) of 154 patients in the abrocitinib 200 mg group, and three (4%) of 77 patients in the placebo group. No treatment-related deaths were reported.Interpretation Monotherapy with oral abrocitinib once daily was effective and well tolerated in adolescents and adults with moderate-to-severe atopic dermatitis.Funding Pfizer.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(20)30732-7

Cites

28 of 28 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 28 references

Research works printed but not linked: 1

  1. Lebwohl MG, Simpson EL, Bushmakin AG, et al. Validation of the pruritus and symptoms assessment for atopic dermatitis in adults with moderate to severe atopic dermatitis. Georg Rajka International Symposium on Atopic Dermatitis; Utrecht; April 11–13, 2018 (abstr P071).

Cited by

See all 531

Metadata

Authors
Simpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M., Bieber, T., Thyssen, J. P., Yosipovitch, G., Flohr, C., Magnolo, N., Maari, C., Feeney, C., Biswas, P., Tatulych, S., Valdez, H., & Rojo, R.
Affiliations
  • Oregon Health & Science University (US)
  • Sinclair Dermatology (AU)
  • Ludwig-Maximilians-Universität München (DE)
  • University Hospital Carl Gustav Carus (DE)
  • Sheffield Children's Hospital (GB)
  • University of Bonn (DE)
  • University of Copenhagen (DK)
  • University of Miami (US)
  • King's College London (GB)
  • University Hospital Münster (DE)
  • Innovaderm (Canada) (CA)
  • Pfizer (United Kingdom) (GB)
  • Pfizer (United States) (US)
Corresponding author
Rojo, Ricardo
Venue
The Lancet
Publisher
Elsevier BV
Published
2020-07
Volume
396
Issue
10246
Pages
255-266
ISSN
  • 0099-5355 (ISSN-L)
  • 0140-6736
OpenAlex
W3044651017
Cited by
522
References
28
Citations by year
2026: 84 · 2025: 81 · 2024: 86 · 2023: 103 · 2022: 79 · 2021: 75 · 2020: 13
FWCI
49.26
Type
journal article
Language
en
Open access
Licence
  • cc-by-nc-nd
  • www.elsevier.com/tdm/userlicense/1.0/ (tdm)
  • www.elsevier.com/legal/tdmrep-license (tdm)
Locations
  • The Lancet (publishedVersion)
  • PubMed (publishedVersion)
  • White Rose Research Online (University of Leeds, The University of Sheffield, University of York) (acceptedVersion)
  • Research at the University of Copenhagen (University of Copenhagen) (acceptedVersion, cc-by-nc-nd)
  • Minerva Access (University of Melbourne) (submittedVersion)
  • Research Portal (King's College London) (submittedVersion)
Funders
  • Eli Lilly and Company
  • Pfizer
  • Sanofi
  • Regeneron Pharmaceuticals
  • Kiniksa Pharmaceuticals
  • Glenmark Pharmaceuticals
  • National Institute for Health and Care Research
  • British Skin Foundation
  • Lundbeckfonden (R139-2012-12679)
  • Galderma
  • LEO Pharma
Topics
  • Health Sciences › Medicine › Dermatology › Dermatology and Skin Diseases
  • Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Asthma and respiratory diseases
  • Health Sciences › Medicine › Dermatology › Contact Dermatitis and Allergies
Keywords
atopic dermatitis, Janus kinase 1 inhibitor, monotherapy, EASI-75, Investigator's Global Assessment, pruritus, treatment safety, adolescents, adults, dose comparison, oral JAK inhibitor, eczema severity, adverse events, drug discontinuation, serious adverse events
MeSH terms
Administration, Oral, Adolescent, Adult, Aged, Australia, Canada, Child, Dermatitis, Atopic, Double-Blind Method, Eczema, Ethnicity, Europe, Female, Humans, Male, Middle Aged, Placebos, Pyrimidines, Safety, Severity of Illness Index, Sulfonamides, United States, Case-Control Studies, Treatment Outcome, Protein Kinase Inhibitors, Janus Kinase 1

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. https://app.cochat.ai/papers/10.1016/s0140-6736(20)30732-7
The paper
Simpson, E. L., Sinclair, R., Forman, S., Wollenberg, A., Aschoff, R., Cork, M., Bieber, T., Thyssen, J. P., Yosipovitch, G., Flohr, C., Magnolo, N., Maari, C., Feeney, C., Biswas, P., Tatulych, S., Valdez, H., & Rojo, R. (2020). Efficacy and safety of abrocitinib in adults and adolescents with moderate-to-severe atopic dermatitis (JADE MONO-1): a multicentre, double-blind, randomised, placebo-controlled, phase 3 trial. The Lancet. https://doi.org/10.1016/s0140-6736(20)30732-7

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.